Catalyst
Slingshot members are tracking this event:
Ziopharm (ZIOP) to complete Phase 1 trial of Allogeneic CD19-Specific T Cells From Peripheral Blood in HSCT patients by December 2016 - On Hold
Do you think this event is important to the companies below? How will it affect their stock price?
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 18, 2018
Occurred Source:
http://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-reports-status-investigational-new-drug
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1 Study, Allogeneic Hematopoietic Stem Cell Transplant, Cd19, Engineered T-cells, Leukemia, Lymphoma, Hsct, Open-label, Single Arm Study
